Lexeo Therapeutics (NASDAQ:LXEO) Announces Earnings Results, Misses Expectations By $0.19 EPS

Lexeo Therapeutics (NASDAQ:LXEO) released its earnings results on Monday. The company reported ($0.99) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.19), Zacks reports.

Lexeo Therapeutics Trading Down 10.3%

Lexeo Therapeutics stock opened at $2.69 on Monday. The company has a market capitalization of $89.30 million, a price-to-earnings ratio of -0.85 and a beta of 1.27. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01. Lexeo Therapeutics has a 12 month low of $1.45 and a 12 month high of $19.50. The business’s fifty day simple moving average is $3.06 and its two-hundred day simple moving average is $5.14.

Wall Street Analyst Weigh In

A number of equities analysts have commented on LXEO shares. Royal Bank of Canada decreased their price target on Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 25th. HC Wainwright reaffirmed a “buy” rating and issued a $23.00 price target on shares of Lexeo Therapeutics in a research note on Tuesday, April 8th. Leerink Partners decreased their price target on Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a research note on Monday, March 24th. Finally, Chardan Capital decreased their price target on Lexeo Therapeutics from $25.00 to $22.00 and set a “buy” rating on the stock in a research note on Tuesday, April 8th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $22.20.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.